Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Valneva SENASDAQ: VALN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 86.04M shares rose 11.8% year over year, behind the +18.5% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +11.8% toward the trailing-twelve-month pace of +18.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
86.04M-0.8% QoQ
Last fiscal yearDec 2025
84.09M+19.7% YoY
LTMMar 2026
83.89M+18.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.8%——
1 year+19.7%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
84.09M EUR
Year-over-year change
+19.7%
4-year CAGR
+14.6%

Weighted Avg Shares vs competitors

How VALN compares with its peers on the latest reported figures

  • VALN's LTM Mar 2026 weighted avg shares of 83.89M shares is the 7th highest of the 8 companies compared; the peer median is 162.41M shares.
  • Its year-over-year change of +18.5% is the 3rd highest of 8, against a peer median of +3.2%.
  • Over three fiscal years its annual growth of +13.4% compares with a peer median of +27.5%.
VALN Competitors Peer median
Weighted Avg Shares for VALN and competitors
Company Period LTM YoY 3-year CAGR
IBRXImmunityBio, Inc.LTM Sep 20261.03B +20.6%+32.0%
MRNAModerna, Inc.LTM Sep 2026396M +2.3%-0.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
NVAXNovavax, Inc.LTM Mar 2026162.41M +3.2%+27.5%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
PCVXVaxcyte, Inc.LTM Jun 2026139.07M +7.3%+28.0%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
Peer median (excluding VALN) 162.41M+3.2%+27.5%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.